期刊文献+

垂体腺癌的临诊应对 被引量:2

Approach to the patient with pituitary carcinoma
原文传递
导出
摘要 回顾性分析经病理证实的原发性垂体腺癌1例,结合影像学上肿瘤的侵袭性进展过程和临床特征进行分析。垂体腺癌生长迅速,肿瘤生长特点有助于临床诊断;其治疗方案与垂体腺瘤也有所不同。临床上,垂体肿瘤增长迅速并伴有侵袭性时需警惕垂体腺癌的可能性,针对垂体腺癌的临床诊疗,仍需进一步累积经验。 One patient confirmed as pituitary carcinoma by histopathology was retrospectively analyzed according to the great changes of tumor invasive growth in imaging examine and clinical characters. Clinically, pituitary carcinoma quickly grows, and the growth character of tumor is helpful in the diagnosis. Moreover, the treatment for pituitary carcinoma is different from pituitary adenoma. The rapid progress of pituitary adenoma indicates the possibility of primary carcinoma. More experience should be accumulated for the diagnosis and treatment of the disease.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2012年第7期593-596,共4页 Chinese Journal of Endocrinology and Metabolism
基金 基金项目:上海市自然科学基金项目(Z08ZR1413)
关键词 垂体腺癌 侵袭性 诊断 治疗 Pituitary carcinoma Invasive Treatment Diagnosis
  • 相关文献

参考文献11

  • 1Figueiredo EG, Paiva WS, Teixeira MJ. Extremely Late development of pituitary carcinoma after surgery and radiotherapy. J Neurooneol, 2009, 92:219-222.
  • 2Kahsas GA, Nomikos P, Kontogeorgos G, et al. Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab, 2005, 90:3089 -3099.
  • 3Gaffey TA, Scheithauer BW, Lloyd RV, et al. Corticotroph carcinoma of the pituitary: a clinic opathological study report of four cases. JNeurosurg, 2002,96:352-360.
  • 4Jaffrain-Rea ML, Di Stefano D, Minniti G, et al. A critical reappraisal of MIB-I labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer, 2002,9 : 103-113.
  • 5Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res, 2003,63:2251-2255.
  • 6Ragel BT, CouldweU WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus, 2004,16 : ET.
  • 7叶廷亮,孙军,沈朝堃.垂体腺癌11例误诊分析[J].临床误诊误治,1997,10(1):15-16. 被引量:2
  • 8Mountcastle RB, Roof BS, MayfieLd RK, et al. Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitm'y testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci, 1989,298:109-118.
  • 9刘冬戈,满开泉,孙肇武,臧旭.非侵袭性、侵袭性垂体腺瘤与垂体腺癌的p53蛋白异常表达及病理学观察[J].中华肿瘤杂志,1998,20(2):128-128. 被引量:1
  • 10张学新,李建峰,邢鹏辉,刘月平.原发垂体癌1例临床分析及文献复习[J].河北医科大学学报,2008,29(3):414-416. 被引量:3

二级参考文献18

  • 1江昌新,谭郁彬.内分泌器官肿瘤病理学和遗传学[M].北京:人民卫生出版社,2006:154-186.
  • 2Scheithauer BW,Kovacs KT,Laws ER Jr,et al.Pathology of invasive pituitary tumors with special reference to functional classification[J].J Neurosurg,1986,65 (6):733-744.
  • 3Pernieone PJ,Seheithauer BW,Sebo TJ,et al.Pituitary careinoma:a clinico-pathologic study of 15 cases[J].Cancer,1997,79(4):804-812.
  • 4Scheithauer BW,Gaffey TA,Lloyd RV,et al.Pathobiolygy of pituitary adenomas and carcinomas[J].Neurosurgery,2006,59(2):341-353.
  • 5Ragel BT,Couldwell WT.Pituitary earcinoma:a review of the literature[J].Neurosurg Focus,2004,16 (4):El.
  • 6Garrao AF,Sobrinho LG,Pedro-Oliveira,et al.ACTHproducing carcinoma of the pituitary with haematogenic metastases[J].Eur J Endocrinol,1997,137(2):176-180.
  • 7Komori T,Martin WH,Graber AL,et al.Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature[J].Clin Nucl Med,2002,27(3):176-178.
  • 8Eriksson B,Bergstrom M,Sundin A,et al.The role of PET in localization of neuroendocrine and adrenocortical tumors[J].Ann NY Acad Sei,2002,970:159-169.
  • 9Asa SL,Ezzat S.The pathogenesis of pituitary tumours[J].Nat Rev Cancer,2002,2 (11):836-849.
  • 10Pei L,Melmed S,Scheithauer B,et al.H-ras mutation nsin human pituitary carcinoma metastases[J].J Clin Endocrinol Metab,1994,78(4):842-846.

共引文献3

同被引文献41

  • 1Heaney AP. Clinical review: Pituitary carcinoma: difficult diagnosis and treatment [J]. J Clin Endocrinol Metab, 2011, 96(12): 3649-3660.
  • 2Sarsur CA, Oldfield EH. Pituitary carcinoma [J]. Semin Oncol, 2010, 37(6): 591-593.
  • 3Pasquel FJ, Vincentelli C, Brat DJ, et ol. Pituitary carci- noma in situ [J]. Endocr Pratt, 2013, 19(3): 69-73.
  • 4Kovacs K. The 2004 WHO classification of pituitary tumors: comments [J]. Acta Neuropathol, 2006, 111(1): 62-63.
  • 5Lira S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma [J]. Lancet Oncol, 2006, 7(6): 518-520.
  • 6Lv H, Li C, Gui S, et al. Expression of estrogen receptor ot and growth factors in human prolactinoma and its correlation with clinical features and gender [J]. J Endo- crinol Invest, 2012, 35(2): 174-180.
  • 7Vieira Nero L, Chimelli L, Pereira PJ, et ol. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma [J]. Endocr Pract, 2013, 19(6): 145-149.
  • 8Raymond E, Dahan L, Raoul JL, et 01. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [J]. N Engl J Med, 2011,364(6): 501-513.
  • 9Amar AP, Hinton DR, Krieger MD, et al. Invasive pituitary adenomas: significance of proliferation parameters [ J ]. Pituitary, 1999, 2(2) :117-122.
  • 10Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody [ J ]. Neurosurgery, 1996, 38 ( 1 ) :99-106 ; discussion 106-107.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部